Trial Profile
Intravitreal Aflibercept (Eylea) for therapy of choroidal neovascularization and fibrovascular proliferation in patients with Pseudoxanthoma elasticum
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Choroidal neovascularisation
- Focus Therapeutic Use
- Acronyms EyNep
- 09 Sep 2018 Status changed to completed.
- 03 May 2018 Planned End Date changed from 1 Feb 2018 to 1 Jul 2018.
- 03 May 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Jul 2018.